Tadacip by Cipla: Tadalafil Product and Market Guide

Tadacip is a tadalafil brand documented in Australia under Cipla Australia Pty Ltd. Current Therapeutic Goods Administration records show different regulatory and supply outcomes by strength. TADACIP 5 and TADACIP 20 have ARTG records with licence status “A.” TADACIP 10 also retains an ARTG record with licence status “A,” while the separate TGA supply database lists it as discontinued with deletion from market effective 1 February 2026 and reduction in supply until exhausted. TADACIP 2.5 was cancelled effective 30 June 2025.

Those records show why a historical list of “Tadacip 2.5/5/10/20 mg” is not a reliable statement of current market status. Registration, cancellation and supply are separate questions. DailyMed retains a Cipla USA tadalafil label covering 2.5 mg, 5 mg, 10 mg and 20 mg strengths. The label and its product identifiers are useful for U.S. product comparison, but the label alone should not be used to infer current U.S. market availability; these products should not automatically be called Tadacip.

Product at a Glance

• Brand: Tadacip
• Active ingredient: tadalafil
• Dosage form: film-coated tablet
• Verified market: Australia
• Australian sponsor: Cipla Australia Pty Ltd
• 5 mg: current ARTG page shows licence status A
• 20 mg: current ARTG page shows licence status A
• 10 mg: ARTG record shows licence status A; separate TGA supply information lists status “Discontinued,” deletion from market on 1 February 2026 and reduction in supply until exhausted
• 2.5 mg: ARTG cancellation took effect 30 June 2025
• U.S. relationship: Cipla USA has separate generic tadalafil labeling and NDCs

What Is Tadacip?

Tadacip is a tadalafil product name used in the Australian market. TGA registration records for the brand identify tadalafil as the active ingredient and Cipla Australia Pty Ltd as sponsor. The Australian registration family historically included 2.5 mg, 5 mg, 10 mg and 20 mg film-coated tablets, but the present status is no longer uniform across those strengths.

That distinction is central to product research. “Tadalafil” identifies an active ingredient. “Tadacip” identifies a brand/product family in a particular market. “Cipla tadalafil” can refer more broadly to tadalafil products associated with Cipla in multiple markets. These labels overlap, but they are not interchangeable.

Who Makes or Sponsors Tadacip?

The current TGA records identify Cipla Australia Pty Ltd as the Australian sponsor for the Tadacip products reviewed here. In practical regulatory terms, the sponsor is the entity responsible for the therapeutic good on the Australian register. The Cipla corporate relationship therefore matters, but the Australian record should still be read at product level: brand, strength, ARTG number and status.

For company-level information, see Cipla Limited. For detailed information about Cipla 526 and Cipla’s wider tadalafil products, see the Cipla tadalafil guide. The Tadacip information below focuses on the brand’s Australian strength-specific records and current status.

Tadacip Strengths and Current Market Status

The 5 mg and 20 mg ARTG pages currently show licence status “A.” The 10 mg ARTG page also shows licence status “A,” but the separate TGA medicine-supply database records TADACIP 10 as “Discontinued,” with deletion from market effective 1 February 2026 and reduction in supply until exhausted. Regulatory status and current supply status therefore need to be read separately; neither an ARTG listing nor licence status “A” proves pharmacy-level stock.

TADACIP 2.5 has a different history again. The TGA cancellation notice states that the product was cancelled under section 30(1)(c), effective 30 June 2025. A marketplace or drug-information page that still lists all four strengths without status dates can therefore be historically accurate yet commercially misleading.

Tadacip vs Cipla Generic Tadalafil in the United States

The U.S. Cipla tadalafil label is a separate product record from Australian Tadacip. DailyMed identifies a Cipla USA tadalafil tablet label covering 2.5 mg, 5 mg, 10 mg and 20 mg strengths. The label is under the generic name tadalafil, with Cipla USA Inc. identified as labeler/registrant. The label provides its own NDCs and product markings; it should not by itself be treated as proof of current U.S. retail availability.

That does not make every Cipla tadalafil tablet “Tadacip.” The Australian Tadacip brand and the U.S. generic tadalafil line share the same active ingredient, but they are differentiated by brand identity, market, sponsor/labeler context, package identifiers and regulatory records. A person trying to verify a product should start with the exact package rather than using the corporate manufacturer name as a substitute for the product name.

Tadacip vs “Cipla 526”

For detailed information about “Cipla 526” and Cipla’s wider tadalafil products, see the Cipla tadalafil page. Tadacip should be identified from its own brand, market and product records rather than from a different tablet identifier.

The useful rule is simple: an imprint, NDC or tablet identifier must be matched to its own U.S. label, while “Tadacip” should be used only when the product record or package actually identifies that brand. Two Cipla-associated products can contain tadalafil and still represent different regulatory and commercial identities.

Why Tadacip Product Lists Can Become Outdated

Drug lists age quickly when they collapse several different statuses into one word such as “available.” Tadacip provides a clear example:

• Historical registration means a product entered the register at some point; it does not prove current supply.
• Active registration describes the current status of a regulatory record; it is not a real-time inventory statement.
• Discontinuation means a sponsor has stopped or is stopping market supply, even if remaining stock may still exist temporarily.
• Supply exhaustion means remaining product may continue to move through the supply chain for a period after the discontinuation decision.
• Cancellation is a regulatory action affecting the ARTG entry itself.

For TADACIP 10, the ARTG page and the supply database answer different questions: the ARTG record currently shows licence status “A,” while the supply database records discontinuation and deletion from market effective 1 February 2026. For TADACIP 2.5, the regulator published a cancellation effective 30 June 2025. Strength-specific status and dates are therefore more informative than a historical list of four Tadacip strengths.

Price and Availability Context

A useful Tadacip price comparison must identify the market, strength, pack, pharmacy and current supply status. A historical online price for 10 mg does not demonstrate that the product remains in normal Australian distribution after the TGA-listed February 2026 deletion from market. Likewise, a price for generic tadalafil in the United States is not automatically a Tadacip price simply because Cipla is involved.

For 5 mg and 20 mg, the current ARTG pages establish licence status “A,” but they do not establish pharmacy-level stock. For 10 mg, the separate TGA supply record makes the discontinuation and 1 February 2026 deletion-from-market date material to any availability claim. For 2.5 mg, the 30 June 2025 cancellation date should be disclosed when older product lists are compared.

Paulsen’s Pharmacy is not represented here as stocking, selling, importing, sourcing or shipping Tadacip, and this page does not publish a Paulsen’s retail price.

How to Verify a Tadacip Product

When checking a Tadacip listing or package, match the following fields rather than relying on the brand name alone:

• Brand: Tadacip
• Active ingredient: tadalafil
• Strength: identify the exact labeled strength
• Dosage form: film-coated tablet in the Australian records reviewed here
• Sponsor: Cipla Australia Pty Ltd for the TGA records used here
• Country: confirm that the product is being evaluated under the Australian record rather than a different market
• ARTG number: match the strength-specific registration
• Supply status: check the TGA shortage/discontinuation database, not only the ARTG listing
• Package identifiers: use current package or label information where available

For a U.S. Cipla tadalafil package, use the corresponding DailyMed/FDA labeling and NDC instead of an Australian Tadacip ARTG number. That prevents a common product-research error: treating the same active ingredient from the same corporate group as one global product.

Prescription and Safety Context

Tadacip is part of Australia’s prescription-medicine framework, and tadalafil labeling includes important contraindications and interaction warnings. U.S. Cipla tadalafil labeling, for example, contraindicates use with organic nitrates and with guanylate-cyclase stimulators such as riociguat. This guide is not a dosing guide; product selection and use should follow the prescribing information for the exact product and market.

Related Cipla Medicines

For Cipla 526 and other Cipla tadalafil product-identification details, see Tadalafil-Based ED Drugs by Cipla Limited. For company-level information, see Cipla Limited. Tadacip is discussed here by its own brand identity, Australian strength-specific records and its distinction from U.S. Cipla generic tadalafil.

Sources and Product-Status Verification

• Therapeutic Goods Administration — TADACIP 5, ARTG 274230
• Therapeutic Goods Administration — TADACIP 20, ARTG 274228
• Therapeutic Goods Administration — TADACIP 10, ARTG 274224
• Therapeutic Goods Administration — tadalafil supply/discontinuation information
• Therapeutic Goods Administration — TADACIP 2.5 cancellation
• DailyMed — Cipla USA tadalafil tablets

Product/status information checked: October 2026.